WO2009045412A3 - Methods of treatment using modified plasminogen activator inhibitor type-1 molecules - Google Patents
Methods of treatment using modified plasminogen activator inhibitor type-1 molecules Download PDFInfo
- Publication number
- WO2009045412A3 WO2009045412A3 PCT/US2008/011330 US2008011330W WO2009045412A3 WO 2009045412 A3 WO2009045412 A3 WO 2009045412A3 US 2008011330 W US2008011330 W US 2008011330W WO 2009045412 A3 WO2009045412 A3 WO 2009045412A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- plasminogen activator
- activator inhibitor
- molecules
- inhibitor type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
The present invention generally relates to methods of treating bleeding diseases and disorders and to promote wound healing. The methods comprises administering a procoagulant, preferably factor VII a, and a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of the PAI-1 molecule. The invention also relates to methods of treating respiratory diseases using a modified PAI-1 molecule.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97665107P | 2007-10-01 | 2007-10-01 | |
US60/976,651 | 2007-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009045412A2 WO2009045412A2 (en) | 2009-04-09 |
WO2009045412A3 true WO2009045412A3 (en) | 2010-01-21 |
Family
ID=40526878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/011330 WO2009045412A2 (en) | 2007-10-01 | 2008-10-01 | Methods of treatment using modified plasminogen activator inhibitor type-1 molecules |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009045412A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2150273A4 (en) * | 2007-04-27 | 2010-11-17 | Univ Toledo | Modified plasminogen activator inhibitor type-1 molecule and methods based thereon |
CN106212126A (en) * | 2016-08-11 | 2016-12-14 | 邱文娟 | A kind of prevention and controls of Fructus Pruni pseudocerasi bleeding disease |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039028A1 (en) * | 1996-04-12 | 1997-10-23 | American National Red Cross | Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof |
WO1998058661A1 (en) * | 1997-06-23 | 1998-12-30 | Novo Nordisk A/S | Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function |
WO2003039580A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides |
WO2003080646A2 (en) * | 2002-03-04 | 2003-10-02 | Medical College Of Ohio | Modified plasminogen activator inhibitor type-1 and methods based thereon |
WO2004056384A2 (en) * | 2002-12-20 | 2004-07-08 | Novo Nordisk Health Care Ag | Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix |
WO2005107795A1 (en) * | 2004-05-11 | 2005-11-17 | Novo Nordisk Health Care Ag | Use of factor viia for the treatment of burn traumas |
-
2008
- 2008-10-01 WO PCT/US2008/011330 patent/WO2009045412A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039028A1 (en) * | 1996-04-12 | 1997-10-23 | American National Red Cross | Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof |
WO1998058661A1 (en) * | 1997-06-23 | 1998-12-30 | Novo Nordisk A/S | Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function |
WO2003039580A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides |
WO2003080646A2 (en) * | 2002-03-04 | 2003-10-02 | Medical College Of Ohio | Modified plasminogen activator inhibitor type-1 and methods based thereon |
WO2004056384A2 (en) * | 2002-12-20 | 2004-07-08 | Novo Nordisk Health Care Ag | Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix |
WO2005107795A1 (en) * | 2004-05-11 | 2005-11-17 | Novo Nordisk Health Care Ag | Use of factor viia for the treatment of burn traumas |
Non-Patent Citations (4)
Title |
---|
CATE JACQUELINE M ET AL: "Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent", CURRENT DRUG TARGETS, vol. 8, no. 9, September 2007 (2007-09-01), pages 971 - 981, XP008115249, ISSN: 1389-4501 * |
DE TAEYE B ET AL: "The story of the serpin plasminogen activator inhibitor I: Is there any need for another mutant?", THROMBOSIS AND HAEMOSTASIS 200411 DE, vol. 92, no. 5, November 2004 (2004-11-01), pages 898 - 924, XP008115403, ISSN: 0340-6245 * |
RENCKENS ROSEMARIJN ET AL: "Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia", BLOOD, vol. 109, no. 4, February 2007 (2007-02-01), pages 1593 - 1601, XP002557166, ISSN: 0006-4971 * |
SISSON T H ET AL: "The plasminogen activation system in lung disease", CURRENT DRUG TARGETS 200709 NL, vol. 8, no. 9, September 2007 (2007-09-01), pages 1016 - 1029, XP008115250, ISSN: 1389-4501 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009045412A2 (en) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA98125C2 (en) | Substituted dihydropyrazolon for the treatment of cardiovascular and haematological diseases | |
EA200970791A1 (en) | N-ADAMANTYLBENZAMIDES AS INHIBITORS 11-β-HYDROXYSTEROID DEHYDROGENASE | |
MY173994A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
MX2009002205A (en) | Methods, compositions and apparatuses to treat wounds with pressures altered from atmospheric. | |
MX353964B (en) | Therapeutic agents and uses thereof. | |
HK1122803A1 (en) | ||
MY161844A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
EP2484344A3 (en) | Compositions and methods of using microspheres and non-ionic contrast agents | |
WO2008101907A3 (en) | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase | |
WO2007100675A3 (en) | Collagenase for treating cellulite | |
MX2010004074A (en) | Combination 059. | |
WO2007058990A3 (en) | Therapy using cytokine inhibitors | |
DE602005018763D1 (en) | DOPAMINE AGONIST COMBINATION THERAPY WITH SEDATIVA TO IMPROVE THE SLEEP QUALITY | |
EP2759302A3 (en) | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
WO2008103345A3 (en) | Hemostatic compositions and therapeutic regimens | |
AU2008267058A8 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
ATE476972T1 (en) | USE OF VALPROIC ACID FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ACNE VULGARIS | |
MX2009011900A (en) | Diabetic wound healing. | |
WO2007130501A3 (en) | Combination therapy for treatment of cancer | |
TW200724146A (en) | Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant | |
MX2007002903A (en) | Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis. | |
WO2010075287A3 (en) | Compounds and methods for the treatment of pain and other diseases | |
GB2446341A (en) | Method and system for transdermal drug delivery | |
WO2009045412A3 (en) | Methods of treatment using modified plasminogen activator inhibitor type-1 molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08836132 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08836132 Country of ref document: EP Kind code of ref document: A2 |